Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounja
GLP-1 weight-loss drug boom may jeopardize global insulin access
- GLP-1 production surge diverts capacity from essential insulin manufacturing
| Asset | Bias | Rationale |
|---|---|---|
| Lilly (Eli)STOCKLLY | 🔒 Members only | 🔒 Members only |
- Global insulin price index
- Emerging-market diabetes medicine access reports
- Insulin-related capex share in NVO/LLY earnings calls
The invalidation conditions are members-only — knowing what would prove this wrong matters as much as the call itself. Unlock full analysis
Public information plus VolFlash reasoning. Not investment advice; no price targets.
The 8 highest-severity events of the past 24h, with our read and source links. Unsubscribe anytime.
Published：2026-11-10 13:24:10 · Source：guardian · Automatically aggregated and analysed — verify against the original source.